N6-methyladenosine-mediated gene regulation and therapeutic implications

被引:55
|
作者
Liu, Yujiao [1 ]
Yang, Dan [1 ]
Liu, Tao [1 ]
Chen, Jianjun [2 ]
Yu, Jianhua [1 ,3 ,4 ]
Yi, Ping [1 ]
机构
[1] Chongqing Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 3, Chongqing 401120, Peoples R China
[2] City of Hope, Beckman Res Inst, Dept Syst Biol, Los Angeles, CA 91010 USA
[3] City Hope Natl Med Ctr, Hematol Malignancies Res Inst, Los Angeles, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Los Angeles, CA 91010 USA
关键词
MESSENGER-RNA; HEPATOCELLULAR-CARCINOMA; MOLECULAR-MECHANISMS; PHASE-SEPARATION; SELF-RENEWAL; N-6-METHYLADENOSINE; FTO; METHYLATION; EXPRESSION; TRANSLATION;
D O I
10.1016/j.molmed.2023.03.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
N6-methyladenosine (m6A) RNA methylation is the most abundant form of mRNA modification in eukaryotes and is at the front line of biological and biomedical re-search. This dynamic and reversible m6A RNA modification determines the fates of modified RNA molecules at the post-transcriptional level, affecting almost all important biological processes. Notably, m6A is also involved in chromatin and transcriptional regulation, while m6A dysregulation is implicated in various dis-eases. Here, we review current knowledge of post-transcriptional and transcrip-tional regulatory mechanisms involving m6A modification. We also discuss their involvement in the occurrence and development of diseases, including cancer, as well as potential theranostic targets, in hope of facilitating the translation of preclinical findings to the clinic.
引用
收藏
页码:454 / 467
页数:14
相关论文
共 50 条
  • [41] N6-methyladenosine-mediated upregulation of H19 promotes resistance to bortezomib by modulating the miR-184/CARM1 axis in multiple myeloma
    Wang, Gang
    Wu, Wenping
    He, Donghua
    Wang, Jiaheng
    Kong, Hongwei
    Wu, Wenjun
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
  • [42] N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer
    Lai, Shihui
    Wang, Yan
    Li, Ting
    Dong, Yihong
    Lin, Yihao
    Wang, Liang
    Weng, Shangeng
    Zhang, Xiang
    Lin, Chengjie
    CELL AND BIOSCIENCE, 2022, 12 (01):
  • [43] Research progress on N6-Methyladenosine modification in angiogenesis, vasculogenic mimicry, and therapeutic implications in breast cancer
    Weng, Jiachen
    Shan, Yisi
    Chang, Qingyu
    Cao, Chenyan
    Liu, Xuemin
    PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2025, 195 : 57 - 70
  • [44] Reversible N6-methyladenosine of RNA: The regulatory mechanisms on gene expression and implications in physiology and pathology
    Fang, Xinyu
    Li, Mengyang
    Yu, Tao
    Liu, Gaoli
    Wang, Jianxun
    GENES & DISEASES, 2020, 7 (04) : 585 - 597
  • [45] N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/b-Catenin and Hippo Signaling Pathways
    Wang, Jinghan
    Yu, Hongming
    Dong, Wei
    Zhang, Cheng
    Hu, Mingtai
    Ma, Wencong
    Jiang, Xiaoqing
    Li, Hengyu
    Yang, Pinghua
    Xiang, Daimin
    GASTROENTEROLOGY, 2023, 164 (06) : 990 - 1005
  • [46] The roles and therapeutic implications of messenger RNA internal N7-methylguanosine and N6-methyladenosine modifications in chemoresistance
    Zhao, Zhicong
    Qing, Ying
    Deng, Xiaolan
    Su, Rui
    Chen, Jianjun
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (09):
  • [47] The landscape of epigenetic regulation and therapeutic application of N6-methyladenosine modifications in non-coding RNAs
    Xu, Gui-e
    Zhao, Xuan
    Li, Guoping
    Gokulnath, Priyanka
    Wang, Lijun
    Xiao, Junjie
    GENES & DISEASES, 2024, 11 (05)
  • [48] N6-methyladenosine-mediated LINC01087 promotes lung adenocarcinoma progression by regulating miR-514a-3p to upregulate centrosome protein 55
    Zhang, Xin
    Wang, Dong-Jie
    Jia, Li
    Zhang, Wei
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2024, 40 (09): : 801 - 818
  • [49] Interleukin-37 attenuates aortic valve lesions by inhibiting N6-methyladenosine-mediated interleukin-1 receptor-associated kinase M degradation
    Xian, Gaopeng
    Huang, Rong
    Hu, Dongtu
    Xu, Minhui
    Chen, Yangchao
    Ren, Hao
    Xu, Dingli
    Zeng, Qingchun
    CARDIOVASCULAR RESEARCH, 2025,
  • [50] N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target
    Quan, Chao
    Belaydi, Othmane
    Hu, Jiao
    Li, Huihuang
    Yu, Anze
    Liu, Peihua
    Yi, Zhenglin
    Qiu, Dongxu
    Ren, Wenbiao
    Ma, Hongzhi
    Gong, Guanghui
    Ou, Zhenyu
    Chen, Minfeng
    Sun, Yin
    Chen, Jinbo
    Zu, Xiongbing
    FRONTIERS IN IMMUNOLOGY, 2021, 12